These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15537834)

  • 1. Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner.
    Liu KH; Kim MJ; Jung WM; Kang W; Cha IJ; Shin JG
    Drug Metab Dispos; 2005 Feb; 33(2):209-13. PubMed ID: 15537834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes.
    Kim KA; Kim MJ; Park JY; Shon JH; Yoon YR; Lee SS; Liu KH; Chun JH; Hyun MH; Shin JG
    Drug Metab Dispos; 2003 Oct; 31(10):1227-34. PubMed ID: 12975331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model.
    Hutzler JM; Hauer MJ; Tracy TS
    Drug Metab Dispos; 2001 Jul; 29(7):1029-34. PubMed ID: 11408370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro.
    Liu KH; Kim MJ; Shon JH; Moon YS; Seol SY; Kang W; Cha IJ; Shin JG
    Xenobiotica; 2005 Jan; 35(1):27-38. PubMed ID: 15788366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substrate-dependent effect of acetonitrile on human liver microsomal cytochrome P450 2C9 (CYP2C9) activity.
    Tang C; Shou M; Rodrigues AD
    Drug Metab Dispos; 2000 May; 28(5):567-72. PubMed ID: 10772636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.
    Thijssen HH; Flinois JP; Beaune PH
    Drug Metab Dispos; 2000 Nov; 28(11):1284-90. PubMed ID: 11038154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9.
    Rowland A; Elliot DJ; Knights KM; Mackenzie PI; Miners JO
    Drug Metab Dispos; 2008 May; 36(5):870-7. PubMed ID: 18256202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.
    Ko JW; Sukhova N; Thacker D; Chen P; Flockhart DA
    Drug Metab Dispos; 1997 Jul; 25(7):853-62. PubMed ID: 9224780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes.
    Katsuki H; Hamada A; Nakamura C; Arimori K; Nakano M
    Eur J Clin Pharmacol; 2001 Dec; 57(10):709-15. PubMed ID: 11829200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the human P450 enzymes involved in lansoprazole metabolism.
    Pearce RE; Rodrigues AD; Goldstein JA; Parkinson A
    J Pharmacol Exp Ther; 1996 May; 277(2):805-16. PubMed ID: 8627562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.
    Li XQ; Andersson TB; Ahlström M; Weidolf L
    Drug Metab Dispos; 2004 Aug; 32(8):821-7. PubMed ID: 15258107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enantiomer/enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in vitro evaluation of the mechanism.
    Kroemer HK; Fischer C; Meese CO; Eichelbaum M
    Mol Pharmacol; 1991 Jul; 40(1):135-42. PubMed ID: 1857335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
    He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
    Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A.
    Desta Z; Soukhova N; Morocho AM; Flockhart DA
    J Pharmacol Exp Ther; 2001 Aug; 298(2):508-20. PubMed ID: 11454912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative metabolism of lansoprazole by human liver cytochromes P450.
    Pichard L; Curi-Pedrosa R; Bonfils C; Jacqz-Aigrain E; Domergue J; Joyeux H; Cosme J; Guengerich FP; Maurel P
    Mol Pharmacol; 1995 Feb; 47(2):410-8. PubMed ID: 7870052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors.
    Crewe HK; Barter ZE; Yeo KR; Rostami-Hodjegan A
    Biopharm Drug Dispos; 2011 Sep; 32(6):303-18. PubMed ID: 21725985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding.
    Haining RL; Jones JP; Henne KR; Fisher MB; Koop DR; Trager WF; Rettie AE
    Biochemistry; 1999 Mar; 38(11):3285-92. PubMed ID: 10079071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development.
    Mori K; Hashimoto H; Takatsu H; Tsuda-Tsukimoto M; Kume T
    Xenobiotica; 2009 Jun; 39(6):415-22. PubMed ID: 19480547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome P450 2C8 (CYP2C8)-mediated hydroxylation of an endothelin ETA receptor antagonist in human liver microsomes.
    Ma B; Subramanian R; Schrag ML; Rodrigues AD; Tang C
    Drug Metab Dispos; 2004 May; 32(5):473-8. PubMed ID: 15100167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin.
    Bland TM; Haining RL; Tracy TS; Callery PS
    Biochem Pharmacol; 2005 Oct; 70(7):1096-103. PubMed ID: 16112652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.